Literature DB >> 12127160

E-cadherin promoter methylation can regulate its expression in invasive ductal breast cancer tissue in Chinese woman.

Xi-Chun Hu1, Wings T Y Loo, Louis W C Chow.   

Abstract

Promoter methylation is an important mechanism of regulating E-cadherin expression. Methylation-specific PCR (MSP) assay was done to evaluate the promoter methylation status of E-cadherin gene in primary tumor samples from 23 cases of Chinese women with invasive ductal breast cancers. Western blotting assay was employed for E-cadherin and beta-actin expressions. Positive MSP results occurred in 26.1% (6/23) of primary tumor samples and none of four normal skin samples. These molecular events tended to occur in breast cancers associated with poor prognosis. Whereas the mean ratio of CDH1/beta-actin for six MSP-positive cases was 0.0290 +/- 0.0355, the mean ratio for 17 MSP-negative cases was 0.4726 +/- 0.5049 (P = 0.046). In conclusion, aberrant E-cadherin methylation preferentially occurs in invasive ductal breast cancer associated with poor prognosis and is one of the mechanisms of E-cadherin expression silence in breast cancers from Chinese women.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12127160     DOI: 10.1016/s0024-3205(02)01843-x

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  7 in total

1.  Aberrant promoter methylation of the CHD1 gene may contribute to the pathogenesis of breast cancer: a meta-analysis.

Authors:  Xi Gu; Jin-Qi Xue; Xi Zhu; Ming-Shi Ye; Wen-Hai Zhang
Journal:  Tumour Biol       Date:  2014-06-22

2.  Estrogen regulates Snail and Slug in the down-regulation of E-cadherin and induces metastatic potential of ovarian cancer cells through estrogen receptor alpha.

Authors:  Se-Hyung Park; Lydia W T Cheung; Alice S T Wong; Peter C K Leung
Journal:  Mol Endocrinol       Date:  2008-06-11

3.  DNA methylation epigenotypes in breast cancer molecular subtypes.

Authors:  Naiara G Bediaga; Amelia Acha-Sagredo; Isabel Guerra; Amparo Viguri; Carmen Albaina; Irune Ruiz Diaz; Ricardo Rezola; María Jesus Alberdi; Joaquín Dopazo; David Montaner; Mertxe Renobales; Agustín F Fernández; John K Field; Mario F Fraga; Triantafillos Liloglou; Marian M de Pancorbo
Journal:  Breast Cancer Res       Date:  2010-09-29       Impact factor: 6.466

Review 4.  Clinicopathological significance and potential drug target of CDH1 in breast cancer: a meta-analysis and literature review.

Authors:  Ruixue Huang; Ping Ding; Fei Yang
Journal:  Drug Des Devel Ther       Date:  2015-09-18       Impact factor: 4.162

5.  Expression analysis of E-cadherin, Slug and GSK3beta in invasive ductal carcinoma of breast.

Authors:  Chandra P Prasad; Gayatri Rath; Sandeep Mathur; Dinesh Bhatnagar; Rajinder Parshad; Ranju Ralhan
Journal:  BMC Cancer       Date:  2009-09-14       Impact factor: 4.430

6.  Influence of HRH2 promoter polymorphism on aberrant DNA methylation of DAPK and CDH1 in the gastric epithelium.

Authors:  Tomoe Nomura; Tomomitsu Tahara; Hisakazu Shiroeda; Takahiro Minato; Yasuhiro Matsue; Ranji Hayashi; Kazuhiro Matsunaga; Toshimi Otsuka; Masakatsu Nakamura; Nobuyuki Toshikuni; Tomoyuki Shibata; Tomiyasu Arisawa
Journal:  BMC Gastroenterol       Date:  2013-01-02       Impact factor: 3.067

7.  Correlation between CpG methylation profiles and hormone receptor status in breast cancers.

Authors:  Weiwei Feng; Lanlan Shen; Sijin Wen; Daniel G Rosen; Jaroslav Jelinek; Xin Hu; Shaoyi Huan; Miao Huang; Jinsong Liu; Aysegul A Sahin; Kelly K Hunt; Robert C Bast; Yu Shen; Jean-Pierre J Issa; Yinhua Yu
Journal:  Breast Cancer Res       Date:  2007       Impact factor: 6.466

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.